免疫抑制治疗相关的慢性乙型肝炎患者HBV再激活与预防

摘要/Abstract

摘要： 随着越来越多免疫抑制剂和细胞毒性化学疗法的临床应用,乙型肝炎病毒(HBV)的再激活已成为一个严峻问题。HBV再激活可导致患者相关的免疫抑制治疗延迟,造成不良的后果。许多证据表明,如果对患者进行筛查以确定他们的HBV活化风险并在开始免疫抑制治疗之前进行预防性治疗,则可以管理和预防HBV再激活。在本文中,我们讨论了影响HBV激活的风险因素,并概述了预防HBV激活的策略,希望日后给予患者更合理的建议。

关键词: 乙型肝炎病毒, 再激活, 免疫抑制, 预防

贲屹然, 陈国林. 免疫抑制治疗相关的慢性乙型肝炎患者HBV再激活与预防[J]. 肝脏, 2021, 26(9): 1041-1043.

参考文献

[1] Ott JJ,Stevens GA,Groegr J,et al. Global epidemiology of hepatitis B virus infection: new estimates of age - specific HBsAg seroprevalence and endemicity. Vaccine,2012,30: 2212-2219.
[2] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease: the major impact of China. Hepatology,2014,60: 2099-2108.
[3] 鲁凤民,窦晓光,张文宏,等. 慢性乙型肝炎患者血清HBV RNA检测的临床意义. 临床肝胆病杂志,2018,34: 934-938.
[4] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 中华肝脏病杂志,2015,23: 888-905.
[5] McMillan JS,Shaw T,Angus PW,et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology,1995, 22: 36-43.
[6] Yeo W,Chan PK,Zhong S,et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol,2000,62: 299-307.
[7] Yuen MF,Wong DK,Fung J,et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma. Gastroenterology,2008,135: 1192-1199.
[8] Paul S,Dickstein A,Saxena A,et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology,2017,66: 379-388.
[9] Mozessohn L,Chan KKW,Feld JJ,et al. Hepatitis B Reactivation in HBsAg-Negative/HBcAb-Positive Patients Receiving Rituximab for Lymphoma: A Meta-Analysis. J. Viral Hepat,2015,22: 842-849.
[10] Yu S,Luo H,Pan M,et al. Comparison of Entecavir and Lamivudine in Preventing HBV Reactivation in Lymphoma Patients Undergoing Chemotherapy: A Meta-Analysis. Int J Clin Pharm,2016,38: 1035-1043.
[11] Chen WC,Cheng JS,Chiang PH,et al. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy. PLoS One,2015,10: e0131545.
[12] Chen CY,Tien FM,Cheng A,et al. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterol,2018,18: 6.
[13] De Monte A,Courjon J,Anty R,et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol,2016,78: 27-30.
[14] Chen CY,Huang SY,Cheng A,et al. High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS One,2015,10: e0126037.
[15] Sarmati L,Andreoni M,Antonelli G,et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect,2017,23: 935-940.
[16] Buti M,Manzano ML,Morillas RM,et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One,2017,12: e0184550.
[17] Huang H,Cai Q,Lin T,et al. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother,2009,10: 2399-2406.
[18] Lindemann M,Barsegian V,Runde V,et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation,2003,75: 833-838.
[19] Loras C,Gisbert JP,Mínguez M,et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut,2010,59: 1340-1346.
[20] Loras C,Gisbert JP,Saro MC,et al. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohns Colitis,2014,8: 1529-1538.
[21] Loomba R,Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts,management strategies and future directions. Gastroenterology,2017,152: 1297-1309.
[22] Squadrito G,Spinella R,Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol,2014,27: 15-19.
[23] Huang YH,Hsiao LT,Hong YC,et al. Randomised controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol,2013,31: 2765-2772.
[24] Hsu C,Hsiung CA,Su IJ,et al. A revisit of prophylactic lamivudine for chemotherapy- associated hepatitis B reactivation in nonHodgkin’s lymphoma: a randomised trial. Hepatology,2008,47: 844-853.
[25] Torbenson M,Thomas DL. Occult hepatitis B. Lancet Infect Dis,2002,2: 479-486.
[26] Yamada T,Nannya Y,Suetsugu A,et al. Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature. Intern Med,2017,56: 115-118.
[27] Hashino S,Nozawa A,Izumiyama K,et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant,2002,29: 361-363.
[28] Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol,2016,22: 219-237.
[29] Takahata M,Hashino S,Onozawa M,et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in nonresponders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis,2014,16: 797-801.